CDKN2A is considered to play a key clinical role in assessing various prognostic mechanisms of endometrial cancer (16, 27, 28), possibly related to cell cycle dysregulation caused by CDKN2A deletion (29). This evidence concerns the gene CDKN2A and endometrial cancer.